Clinverse Introduces ClinPlan
Clinverse, Inc., provider of automated financial management technology solutions for clinical trials, announced today that it has expanded its suite of products with the addition of ClinPlan™, purpose-built software for clinical trial budget management and forecasting.
Clinverse has expanded its suite of products with the addition of ClinPlan™, software for clinical trial budget management and forecasting. ClinPlan provides clients with the ability to consolidate budgets from the variety of vendors and sources that contribute to the total trial expense. The solution also imports site activation data and schedule of assessments and related expenses to allow the cost over time to be evaluated and reevaluated using actual data once the trial begins.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
